» Articles » PMID: 18535913

Epithelial to Mesenchymal Transition (EMT) in Human Prostate Cancer: Lessons Learned from ARCaP Model

Overview
Specialty Oncology
Date 2008 Jun 7
PMID 18535913
Citations 87
Authors
Affiliations
Soon will be listed here.
Abstract

Androgen refractory cancer of the prostate (ARCaP) cells contain androgen receptor (AR) and synthesize and secrete prostate specific antigen (PSA). We isolated epithelia-like ARCaP(E) from parental ARCaP cells and induced them to undergo epithelial-mesenchymal transition (EMT) by exposing these cells to soluble factors including TGFbeta1 plus EGF, IGF-1, beta2-microglobulin (beta2-m), or a bone microenvironment. The molecular and behavioral characteristics of the resultant ARCaP(M) were characterized extensively in comparison to the parental ARCaP(E) cells. In addition to expressing mesenchymal biomarkers, ARCaP(M) gained 100% incidence of bone metastasis. ARCaP(M) cells express receptor activator of NF-kappaB ligand (RANKL), which was shown to increase tartrate-resistant acid phosphatase (TRAP)-positive osteoclasts in culture, and when metastatic to bone in vivo. We provide evidence that RANKL expression was promoted by increased cell signaling mediated by the activation of Stat3-Snail-LIV-1. RANKL expressed by ARCaP(M) cells is functional both in vitro and in vivo. The lesson we learned from the ARCaP model of EMT is that activation of a specific cell signaling pathway by soluble factors can lead to increased bone turnover, mediated by enhanced RANKL expression by tumor cells, which is implicated in the high incidence of prostate cancer bone colonization. The ARCaP EMT model is highly attractive for developing new therapeutic agents to treat prostate cancer bone metastasis.

Citing Articles

The role of proinflammatory cytokines and CXC chemokines (CXCL1-CXCL16) in the progression of prostate cancer: insights on their therapeutic management.

Ullah A, Jiao W, Shen B Cell Mol Biol Lett. 2024; 29(1):73.

PMID: 38745115 PMC: 11094955. DOI: 10.1186/s11658-024-00591-9.


Extracellular Mechanical Stimuli Alters the Metastatic Progression of Prostate Cancer Cells within 3D Tissue Matrix.

Ditto M, Jacho D, Eisenmann K, Yildirim-Ayan E Bioengineering (Basel). 2023; 10(11).

PMID: 38002395 PMC: 10669840. DOI: 10.3390/bioengineering10111271.


KRT13 promotes stemness and drives metastasis in breast cancer through a plakoglobin/c-Myc signaling pathway.

Yin L, Li Q, Mrdenovic S, Chu G, Wu B, Bu H Breast Cancer Res. 2022; 24(1):7.

PMID: 35078507 PMC: 8788068. DOI: 10.1186/s13058-022-01502-6.


A Double-Edged Sword Role of Cytokines in Prostate Cancer Immunotherapy.

Mao C, Ding Y, Xu N Front Oncol. 2021; 11:688489.

PMID: 34868907 PMC: 8635015. DOI: 10.3389/fonc.2021.688489.


Studies of hormonal regulation, phenotype plasticity, bone metastasis, and experimental therapeutics in androgen-repressed human prostate cancer (ARCaP) model.

Lo U, Chen Y, Khamis Z, Kao W, Hsieh J, Sang Q Am J Clin Exp Urol. 2021; 9(4):277-286.

PMID: 34541026 PMC: 8446760.


References
1.
Taylor K, Hiscox S, Nicholson R . Zinc transporter LIV-1: a link between cellular development and cancer progression. Trends Endocrinol Metab. 2004; 15(10):461-3. DOI: 10.1016/j.tem.2004.10.003. View

2.
Kawakami K . Cancer gene therapy utilizing interleukin-13 receptor alpha2 chain. Curr Gene Ther. 2005; 5(2):213-23. DOI: 10.2174/1566523053544227. View

3.
Thiery J, Sleeman J . Complex networks orchestrate epithelial-mesenchymal transitions. Nat Rev Mol Cell Biol. 2006; 7(2):131-42. DOI: 10.1038/nrm1835. View

4.
Robinson V, Kauffman E, Sokoloff M, Rinker-Schaeffer C . The basic biology of metastasis. Cancer Treat Res. 2004; 118:1-21. DOI: 10.1007/978-1-4419-9129-4_1. View

5.
Huang W, Wu D, Xie Z, Zhau H, Nomura T, Zayzafoon M . beta2-microglobulin is a signaling and growth-promoting factor for human prostate cancer bone metastasis. Cancer Res. 2006; 66(18):9108-16. DOI: 10.1158/0008-5472.CAN-06-1996. View